Overview of immune checkpoint inhibitors therapy for hepatocellular carcinoma, and the ITA.LI.ca cohort derived estimate of amenability rate to immune checkpoint inhibitors in clinical practice

Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group, E.G. Giannini, A. Aglitti, M. Borzio, M. Gambato, M. Guarino, M. Iavarone, Q. Lai, G.B.L. Sandri, F. Melandro, F. Morisco, F.R. Ponziani, M. Rendina, F.P. Russo, R. Sacco, M. Viganò, A. Vitale, F. Trevisani

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Article number1689
Issue number11
Publication statusPublished - 2019


  • Check-point inhibitors
  • Immunotherapy
  • Liver disease
  • Outcome
  • atezolizumab
  • bevacizumab
  • camrelizumab
  • checkpoint kinase inhibitor
  • durvalumab
  • ipilimumab
  • lenvatinib
  • nivolumab
  • pembrolizumab
  • ticilimumab
  • tislelizumab
  • cancer adjuvant therapy
  • cancer combination chemotherapy
  • cancer immunotherapy
  • cellular, subcellular and molecular biological phenomena and functions
  • clinical practice
  • data base
  • drug efficacy
  • human
  • immune checkpoint blockade therapy
  • immunobiology
  • intestine flora
  • liver cell carcinoma
  • molecularly targeted therapy
  • monotherapy
  • nonhuman
  • patient selection
  • response evaluation criteria in solid tumors
  • Review
  • T cell exhaustion
  • treatment response

Cite this